Oxandrolone
Also known as: Anavar, Var, Oxandrin
Oral Anabolic Steroid | Lean Mass & Recovery
Overview
Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings.
Key benefits
- Promotes lean muscle mass gains with minimal water retention
- Supports recovery of lost body weight following surgery, trauma, or chronic illness
- Reduces bone pain associated with osteoporosis and improves bone mineral density
- Does not aromatize to estrogen, avoiding estrogen-related side effects
- Well-studied safety profile in women, children, and burn patients
- Enhances nitrogen retention and protein synthesis during caloric deficit
- Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
- Lower androgenic potency compared to most oral anabolic steroids
Mechanism of action
Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia. The 2-oxo modification in the A-ring reduces its affinity for 5-alpha reductase, limiting conversion to more potent androgens in peripheral tissues and contributing to its relatively low androgenic profile. Oxandrolone increases protein synthesis through direct AR-mediated gene transcription, enhances the expression of genes involved in muscle hypertrophy and repair, and promotes collagen synthesis. It has also been shown to reduce cortisol-binding globulin levels and attenuate the catabolic effects of glucocorticoids, which is particularly relevant in burn patients and those recovering from severe trauma. Additionally, oxandrolone stimulates hepatic production of sex hormone-binding globulin (SHBG) to a lesser degree than other oral steroids, though it does suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis.
Molecular data
- Type
- 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3)
- Half-life
- ~9-10 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Recovery & Wasting
Bone & Joint Health
Body Composition
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 2.5-20 mg/day | Divided into 2-4 doses daily | — |
| — | 0.1 mg/kg twice daily | Twice daily | — |
| — | 20-30 mg/day | Split into 2 doses (morning and evening) | — |
| — | 40-50 mg/day | Split into 2 doses (morning and evening) | — |
| — | 5-20 mg/day | Split into 2 doses or taken once daily | — |
| — | 5-20 mg/day | Once daily or split into 2 doses | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- HDL cholesterol suppression (dose-dependent, most significant lipid effect)
- LDL cholesterol elevation
- Mild hepatic stress (elevated liver enzymes ALT/AST)
- Suppression of endogenous testosterone production
- Mild headaches
- Nausea or gastrointestinal discomfort
- Changes in libido (increase or decrease depending on hormonal context)
- Oily skin and mild acne
Rare side effects
- Hair thinning or accelerated male pattern baldness (dose-dependent, DHT derivative)
- Virilization in women at higher doses (deepening voice, hirsutism, clitoral enlargement)
- Significant hepatotoxicity (much less common than with other 17-alpha-alkylated steroids)
- Peliosis hepatis (blood-filled cysts in the liver, extremely rare)
- Tendon rupture (anecdotal reports of increased tendon fragility with rapid strength gains)
- Mood changes including irritability or anxiety
- Prolonged or persistent suppression of the HPTA axis beyond expected recovery window
Contraindications
- Known or suspected prostate cancer
- Breast cancer in males
- Breast cancer with hypercalcemia in females
- Pregnancy (Category X - known to cause fetal harm)
- Nephrosis or nephrotic phase of nephritis
- Hypercalcemia
- Severe hepatic dysfunction or active liver disease
- Hypersensitivity to oxandrolone or any formulation component
Monitoring
- Lipid panel (total cholesterol, HDL, LDL, triglycerides): baseline, 4 weeks, and every 4-6 weeks during use
- Liver function tests (ALT, AST, bilirubin, ALP): baseline and every 4-6 weeks during use
- Complete blood count: baseline and periodically during treatment
- Fasting glucose and HbA1c in diabetic patients: increased monitoring frequency
- Total and free testosterone, LH, FSH: baseline and post-cycle to assess HPTA recovery
- Serum calcium levels in patients at risk for hypercalcemia (especially cancer patients)
- Bone age studies in pediatric patients to monitor epiphyseal closure
- Virilization assessment in female patients at each follow-up visit
References
Primary literature and clinical-trial data informing this entry.